้ไธ้
้ไธ้ๆฏไธ็จฎ็ญๆ็ๅๆ้ๆฟ็ด ๏ผๅฐไธๆณๅฐฟ็ๆฎ้็้ๆฟ็ด ๅ้ซๅ ทๆ้ซ่ฆชๅๅใไธป่ฆ็จๆผๆฒป็ๅทฒ็ต่ฒๆฏ็ฌ็ๅฐฟ้ๆฌ็ด่ๆฉ่ฝไธๅ จ (USMI)ใ
ไฝ็จๆฉๅถ: Estriol binds to **estrogen receptors** in the lower urogenital tract โ increases resting urethral muscle tone and mucosal vascularity โ improves urodynamic function and urethral closure pressure.
ๅ็ฉ็จฎๅ้
- All indications ยท Do not use. ยท PO ยท N/A ยท N/A ยท Contraindicated or not recommended for use in cats.
- Urethral sphincter mechanism incompetence (USMI) in spayed bitches ยท Starting dose: 1 mg/dog. If successful, reduce to 0.5 mg/dog. If unsuccessful, increase to 2 mg/dog. Minimum effective dose: 0.5 mg/dog. Maximum dose: 2 mg/dog. ยท PO ยท q24h (can consider q48h for maintenance once response is seen) ยท Long-term ยท Alternate-day dosing can be considered once a response has been seen.
ๅ้็บๅๆ ผ็ธ้ซๅฐๆฅญไบบๅก็่จๅบๅ่ใ่ซๅๅฟ ๅฐ็ งๆๆฐ่ฅๅไปฟๅฎๅๅๅฅ็ ๆฃ็ขบ่ชใ
็ตฆ่ฅ้ๅพ
็ฆๅฟ็
- Intact bitches
- Polyuria/polydipsia (PU/PD) of unknown origin
- Animals < 1 year old
ไธ่ฏๅๆ
- Oestrogenic effects (swollen vulva, attractiveness to males) in 5-9% of dogs at 2 mg/day
- Bone marrow suppression (rare, but possible with long-term use)
- Gastrointestinal upset (mild)
่ฅ็ฉ็ธไบไฝ็จ
- Phenylpropanolamine ยท Concurrent administration may potentiate efficacy in treating urinary incontinence (synergistic effect). ยท minor
็ฃๆธฌ
- Clinical response (resolution of urinary incontinence)
- Complete Blood Count (CBC) periodically for long-term use to monitor for bone marrow suppression
- Signs of estrogenic side effects (vulvar swelling)
้้
Overdose may lead to exaggerated estrogenic effects, including pronounced vulvar swelling, attractiveness to male dogs, and potentially an increased risk of **bone marrow suppression** (anemia, thrombocytopenia, leukopenia). Treatment is supportive and symptomatic; discontinue the drug until signs resolve.
VetSheet ่ฅ็ฉๅ่ไพๆ็็ธ้ซๅฐๆฅญไบบๅกไฝ่จๅบๆฑบ็ญ่ผๅฉไน็จ,ไธ่ฝๅไปฃๅฐๆฅญๅคๆทๆๅป ๆนๆๆฐ่ฅๅ่ชชๆๆธใ